Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4283833 | 0.99 | MCHR1 (0.42) | MCHR1KCNH2KDM4EALDH1A1ACHE | |
| SCHEMBL3917777 | 0.92 | MCHR1 (0.44) | MCHR1KCNH2KDM4EALDH1A1CCR3 | |
| Hydrochloric Acid SCHEMBL5007613 | 0.91 | MCHR1 (0.43) | MCHR1KCNH2KDM4EALDH1A1CCR3 | |
| SCHEMBL3917098 | 0.86 | ALDH1A1 (0.45) | MCHR1KCNH2KDM4EALDH1A1RAB9A | |
| SCHEMBL3927696 | 0.84 | ALDH1A1 (0.50) | MCHR1KCNH2KDM4EALDH1A1 | |
| SCHEMBL13448653 | 0.80 | MEN1 (0.41) | MCHR1KDM4EALDH1A1ACHE | |
| SCHEMBL10017899 | 0.79 | RAB9A (0.41) | MCHR1KDM4ENPC1RAB9A | |
| SCHEMBL5004141 | 0.78 | SPHK2 (0.46) | KCNH2KDM4EALDH1A1 | |
| SCHEMBL5007595 | 0.78 | SPHK2 (0.46) | KCNH2KDM4EALDH1A1 | |
| SCHEMBL10049565 | 0.78 | ALOX5 (0.47) | KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188089-B2 | Tylophorine analogs as antitumor agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-29 | — | — | US | disclosed |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | RPL30, RPL18A, RPP30 | MCHR1 238/4885KCNH2 695/4885KDM4E 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.